JP2023550545A5 - - Google Patents

Info

Publication number
JP2023550545A5
JP2023550545A5 JP2023551948A JP2023551948A JP2023550545A5 JP 2023550545 A5 JP2023550545 A5 JP 2023550545A5 JP 2023551948 A JP2023551948 A JP 2023551948A JP 2023551948 A JP2023551948 A JP 2023551948A JP 2023550545 A5 JP2023550545 A5 JP 2023550545A5
Authority
JP
Japan
Prior art keywords
polypeptide
modified
item
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550545A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057741 external-priority patent/WO2022094473A1/en
Publication of JP2023550545A publication Critical patent/JP2023550545A/ja
Publication of JP2023550545A5 publication Critical patent/JP2023550545A5/ja
Pending legal-status Critical Current

Links

JP2023551948A 2020-11-02 2021-11-02 インターロイキン-18バリアントおよび使用の方法 Pending JP2023550545A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108794P 2020-11-02 2020-11-02
US63/108,794 2020-11-02
PCT/US2021/057741 WO2022094473A1 (en) 2020-11-02 2021-11-02 Interleukin-18 variants and methods of use

Publications (2)

Publication Number Publication Date
JP2023550545A JP2023550545A (ja) 2023-12-01
JP2023550545A5 true JP2023550545A5 (cg-RX-API-DMAC7.html) 2024-11-12

Family

ID=81384408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551948A Pending JP2023550545A (ja) 2020-11-02 2021-11-02 インターロイキン-18バリアントおよび使用の方法

Country Status (14)

Country Link
US (3) US11850276B2 (cg-RX-API-DMAC7.html)
EP (1) EP4236990A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023550545A (cg-RX-API-DMAC7.html)
KR (1) KR20230117120A (cg-RX-API-DMAC7.html)
CN (1) CN116723851A (cg-RX-API-DMAC7.html)
AR (1) AR123978A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021371040C1 (cg-RX-API-DMAC7.html)
CA (1) CA3197145A1 (cg-RX-API-DMAC7.html)
GB (1) GB2617483B (cg-RX-API-DMAC7.html)
IL (1) IL302517A (cg-RX-API-DMAC7.html)
MX (1) MX2023005068A (cg-RX-API-DMAC7.html)
NZ (1) NZ800435A (cg-RX-API-DMAC7.html)
TW (1) TW202233657A (cg-RX-API-DMAC7.html)
WO (1) WO2022094473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7795181B2 (ja) 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン-18バリアントとその利用法
WO2023010021A1 (en) 2021-07-27 2023-02-02 Xencor, Inc. Il-18-fc fusion proteins
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
EP4584287A1 (en) * 2022-09-06 2025-07-16 TJ Biopharma (Shanghai) Co., Ltd. Il-18 variant polypeptides
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
EP4655310A2 (en) * 2023-01-24 2025-12-03 Simcha Il-18, Inc. Methods and compositions for combination therapy
WO2024259270A2 (en) * 2023-06-16 2024-12-19 Simcha IL-18, Inc. Administration of engineered interleukin-18 therapeutics
IL325907A (en) 2023-07-13 2026-03-01 Iovance Biotherapeutics Inc Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025085447A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Pd-1 targeted il18-fc fusion proteins
WO2025122614A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
CN120189493A (zh) * 2023-12-22 2025-06-24 广州威溶特医药科技有限公司 Dr-18和m1病毒在制备抗肿瘤药物中的应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
WO2026050249A1 (en) * 2024-08-26 2026-03-05 Simcha IL-18, Inc. Methods of treating cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
EP1669454A3 (en) 1996-06-27 2009-04-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
JP4024366B2 (ja) 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
JP2007143555A (ja) * 1996-11-29 2007-06-14 Hayashibara Biochem Lab Inc ポリペプチド
JP3955352B2 (ja) 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
AU2001275166B2 (en) 2000-06-02 2005-07-28 Smithkline Beecham Corporation Methods of treating viral diseases with il-18 and il-18 combinations
JP2004530432A (ja) 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−18変異体、その産生および使用
US6800479B2 (en) 2001-12-11 2004-10-05 Samyang Genex Corporation Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
EP1613274B1 (en) * 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
WO2011080733A1 (en) * 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
WO2017102010A1 (en) 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
JP7795181B2 (ja) * 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン-18バリアントとその利用法
JP2020143000A (ja) * 2019-03-04 2020-09-10 大陽日酸株式会社 融合タンパク質及びその製造方法、目的タンパク質の製造方法
US12029778B2 (en) * 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
CN116368148A (zh) * 2020-08-19 2023-06-30 明峰治疗股份公司 修饰的il-18多肽及其用途

Similar Documents

Publication Publication Date Title
GB2617483A (en) Interleukin-18 variants and methods of use
US12509494B2 (en) Multi-chain chimeric polypeptides and uses thereof
JP2020533301A5 (cg-RX-API-DMAC7.html)
CN111148756B (zh) T细胞受体
JP2024177464A (ja) サイトカイン融合タンパク質
KR100961054B1 (ko) 암을 치료하기 위해 조작한 신규한 초항원을 포함하는 접합체, 이를 포함하는 조성물 및 이를 사용하는 방법
JP2020512814A (ja) 免疫抱合体
JP2022536898A (ja) 新規il-15プロドラッグおよびその使用方法
CN112654636A (zh) 可活化白介素12多肽及其使用方法
JP2020508691A (ja) Il−12及びil−18へのil−15系融合
Dohlsten et al. Immunotherapy of human colon cancer by antibody-targeted superantigens
CN114502188B (zh) 人工免疫监视嵌合抗原受体及其表达细胞
JP7834360B2 (ja) 改変ブタ膵臓エラスターゼタンパク質
CN114258431A (zh) 重组人唾液酸酶、唾液酸酶融合蛋白及其使用方法
CN113179631A (zh) 通过临近使能反应疗法开发的共价蛋白质药物
US20230218669A1 (en) Augmenting antigen-negative cell death in antigen-targeted immunotherapies
EP4524164A1 (en) Novel fusion protein and use thereof
CA3179805A1 (en) Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein
HK40103019A (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
CN121591912A (zh) 靶向免疫检查点的peg化il-2融合蛋白及其应用
HK40015970B (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15